Karen King

3.6k total citations · 1 hit paper
56 papers, 2.6k citations indexed

About

Karen King is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Karen King has authored 56 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 12 papers in Cancer Research and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Karen King's work include Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Treatment and Pharmacology (7 papers). Karen King is often cited by papers focused on Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Treatment and Pharmacology (7 papers). Karen King collaborates with scholars based in Canada, United States and India. Karen King's co-authors include Charles E. Geyer, Norman Wolmark, Shaker R. Dakhil, Eleftherios P. Mamounas, André Robidoux, Stewart Anderson, Richard G. Margolese, Priya Rastogi, Victor G. Vogel and Morton S. Kahlenberg and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and Cancer Research.

In The Last Decade

Karen King

53 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

2008 1.3k citations Karen King et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karen King Canada	16	1.1k	1.1k	549	382	341	56	2.6k
Günther Gruber Switzerland	15	1.7k 1.5×	1.8k 1.6×	596 1.1×	548 1.4×	421 1.2×	24	3.2k
Angela Moliterni Italy	21	2.1k 1.9×	1.7k 1.5×	605 1.1×	305 0.8×	289 0.8×	35	3.0k
RD Gelber Switzerland	17	1.7k 1.5×	909 0.8×	325 0.6×	465 1.2×	243 0.7×	37	2.7k
Hans‐Joachim Lück Germany	28	1.9k 1.7×	721 0.7×	272 0.5×	298 0.8×	402 1.2×	67	2.9k
E. Shelley Hwang United States	26	1.3k 1.2×	1.8k 1.6×	964 1.8×	483 1.3×	708 2.1×	96	3.3k
Daniel Rayson Canada	32	2.0k 1.8×	885 0.8×	452 0.8×	283 0.7×	274 0.8×	137	3.4k
H.T. Mouridsen Denmark	22	1.4k 1.3×	1.3k 1.2×	438 0.8×	206 0.5×	261 0.8×	49	2.5k
J A Dewar United Kingdom	19	1.3k 1.2×	1.0k 0.9×	357 0.7×	225 0.6×	302 0.9×	46	2.6k
James J. Dignam United States	24	1.8k 1.6×	1.2k 1.1×	651 1.2×	270 0.7×	353 1.0×	55	3.5k
Giuseppe D’Aiuto Italy	28	1.4k 1.2×	1.2k 1.1×	334 0.6×	346 0.9×	266 0.8×	90	2.8k

Countries citing papers authored by Karen King

Since Specialization

Citations

This map shows the geographic impact of Karen King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen King more than expected).

Fields of papers citing papers by Karen King

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen King. The network helps show where Karen King may publish in the future.

Co-authorship network of co-authors of Karen King

This figure shows the co-authorship network connecting the top 25 collaborators of Karen King. A scholar is included among the top collaborators of Karen King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen King. Karen King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Silva, Bruna Ramos da, Amy A. Kirkham, Marı́a Cristina González, et al.. (2024). Evaluating predictive equations for energy requirements throughout breast cancer trajectory: A comparative study. Clinical Nutrition. 43(9). 2073–2082. 5 indexed citations

Black, W. A. P., John R. Mackey, Karen King, et al.. (2023). Does cardiac imaging surveillance strategy influence outcomes in patients with early breast cancer?. Frontiers in Oncology. 13. 1168651–1168651. 1 indexed citations

Oberoi, Devesh, Cynthia Kwok, Yong Li, et al.. (2022). Documenting patients’ and providers’ preferences when proposing a randomized controlled trial: a qualitative exploration. BMC Medical Research Methodology. 22(1). 64–64. 1 indexed citations

Batra, Atul, Nancy Nixon, Malek B. Hannouf, et al.. (2021). Developing a clinical-pathologic model to predict genomic risk of recurrence in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative, node negative breast cancer. Cancer Treatment and Research Communications. 28. 100401–100401. 3 indexed citations

Veitch, Zachary, Domen Ribnikar, Patricia A. Tang, et al.. (2021). No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer. British Journal of Cancer. 126(6). 881–888. 7 indexed citations

Joy, Anil A., Larissa J. Vos, Edith Pituskin, et al.. (2021). Uridine Glucuronosyltransferase 2B7 Polymorphism-Based Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy for Early-Stage Breast Cancer. Clinical Breast Cancer. 21(5). e584–e593. 3 indexed citations

Kirkham, Amy A., Karen King, Anil A. Joy, et al.. (2021). Rationale and design of the Diet Restriction and Exercise-induced Adaptations in Metastatic breast cancer (DREAM) study: a 2-arm, parallel-group, phase II, randomized control trial of a short-term, calorie-restricted, and ketogenic diet plus exercise during intravenous chemotherapy versus usual care. BMC Cancer. 21(1). 1093–1093. 27 indexed citations

Lupichuk, Sasha, et al.. (2020). Unwarranted imaging for distant metastases in patients with newly diagnosed ductal carcinoma in situ and stage I and II breast cancer. Canadian Journal of Surgery. 63(2). E100–E109. 6 indexed citations

Veitch, Zachary, Omar Khan, Xanthoula Kostaras, et al.. (2019). Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer. Journal of the National Comprehensive Cancer Network. 17(1). 47–56. 4 indexed citations

10.

Sawyer, Michael B., Edith Pituskin, Sambasivarao Damaraju, et al.. (2015). A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. Clinical Breast Cancer. 16(2). 139–144.e3. 17 indexed citations

11.

Li, Xue, Andrew Scarfe, Karen King, et al.. (2013). Timeliness of cancer care from diagnosis to treatment: a comparison between patients with breast, colon, rectal or lung cancer. International Journal for Quality in Health Care. 25(2). 197–204. 30 indexed citations

12.

Butts, Charles, et al.. (2011). Utilization of oncology services and receipt of treatment: a comparison between patients with breast, colon, rectal, or lung cancer. Annals of Oncology. 22(8). 1902–1909. 12 indexed citations

13.

Tsang, Roger Y., C.L. Santos, Sunita Ghosh, et al.. (2008). Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia. Modern Pathology. 21(11). 1387–1393. 11 indexed citations

14.

King, Karen & K. Bruce Newbold. (2007). Internal Migration Dynamics of a Canadian Immigrant Gateway: Toronto as an Origin, Way-Station and Destination between 1991 and 2001 */la Dynamique De la Migration Interne D'une Porte D'entree Canadienne : Toronto En Tant Qu'origine, Etape et Destination Entre 1991 et 2001. Canadian Journal of Regional Science. 30(2). 243. 7 indexed citations

15.

King, Karen & K. Bruce Newbold. (2007). Onward Emigration to the United States by Canadian Immigrants between 1995 and 2000 . International Migration Review. 41(4). 909–929. 25 indexed citations

16.

Zhang, Jing, Frank Visser, Karen King, et al.. (2007). The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer and Metastasis Reviews. 26(1). 85–110. 188 indexed citations

17.

King, Karen, Vijaya L. Damaraju, Mark F. Vickers, et al.. (2005). A Comparison of the Transportability, and Its Role in Cytotoxicity, of Clofarabine, Cladribine, and Fludarabine by Recombinant Human Nucleoside Transporters Produced in Three Model Expression Systems. Molecular Pharmacology. 69(1). 346–353. 83 indexed citations

18.

Topp, Robert, et al.. (2002). The Effect of Bed Rest and Potential of Prehabilitation on Patients in the Intensive Care Unit. AACN Clinical Issues Advanced Practice in Acute & Critical Care. 13(2). 263–276. 238 indexed citations

19.

Mosca, Lori, Debra R. Judelson, Karen King, et al.. (1999). Discussion. Journal of the American College of Cardiology. 33(6). 1751–1755. 87 indexed citations

20.

Kirkpatrick, D. Lynn, et al.. (1992). Effect of a hypoxic tumor cell cytotoxic disulfide on the membrane and DNA of tumor cells in culture. Anti-Cancer Drugs. 3(6). 651–658. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact